Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer (Q33511035)

27 July 2017

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer (English)

1 reference

27 July 2017

Robert M Mader

8

0 references

Michael Gnant

object named as

Michael Gnant

11

0 references

author name string

Rupert Bartsch

1

1 reference

27 July 2017

Catharina De Vries

2

1 reference

27 July 2017

Ursula Pluschnig

3

1 reference

27 July 2017

Peter Dubsky

4

1 reference

27 July 2017

Zsuzsanna Bago-Horvath

5

1 reference

27 July 2017

Simon P Gampenrieder

6

1 reference

27 July 2017

Margaretha Rudas

7

1 reference

27 July 2017

Andrea Rottenfusser

9

1 reference

27 July 2017

Christoph Wiltschke

10

1 reference

27 July 2017

Christoph C Zielinski

12

1 reference

27 July 2017

Guenther G Steger

13

1 reference

27 July 2017

language of work or name

English

0 references

publication date

17 October 2009

1 reference

27 July 2017

1 reference

27 July 2017

9

1 reference

27 July 2017

367

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-9-367

27 July 2017

0 references

cites work

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770076

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770076

Phosphoproteomic analysis of Her2/neu signaling and inhibition

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770076

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770076

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770076

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770076

Trastuzumab-associated cardiotoxicity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770076

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770076

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770076

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770076

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770076

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770076

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770076

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770076

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770076

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-9-367

Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-9-367

Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-9-367

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19835621

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19835621

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-9-367

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference